Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech

Kineta Chronic Pain, LLC, a subsidiary of Kineta, Inc., today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists for the treatment of chronic pain.

• Source: Kinetabio
• 476
• April 18, 2018